{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:29:36Z","timestamp":1791606576100,"version":"4.3.4"},"reference-count":11,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.euf.2023.11.007","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T10:40:33Z","timestamp":1700649633000},"page":"564-566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Quinolone Prophylaxis in Conjunction with Bacillus Calmette-Gu\u00e9rin Instillations for Bladder Cancer: Time To Reconsider the Evidence and Open the Quinolone Box?"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8193-0370","authenticated-orcid":false,"given":"Fredrik","family":"Liedberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2023.11.007_b0005","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2023.11.007_b0010","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.euf.2022.06.002","article-title":"Effect of levofloxacin on the efficacy and adverse events in intravesical bacillus Calmette-Guerin treatment for bladder cancer: results of a randomized, prospective, multicenter study","volume":"8","author":"Numakura","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2023.11.007_b0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"Suppl 1","key":"10.1016\/j.euf.2023.11.007_b0020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000052378","article-title":"Sensitivity of BCG to modern antibiotics","volume":"37","author":"Durek","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2023.11.007_b0025","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","article-title":"The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study","volume":"176","author":"Colombel","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2023.11.007_b0030","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1464-410X.2009.08469.x","article-title":"Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Gu\u00e9rin-induced toxicity?","volume":"104","author":"Damiano","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2023.11.007_b0035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.urology.2021.06.032","article-title":"Prospective phase II study to evaluate response to two induction courses (12 intravesical instillations) of BCG therapy for high-risk non-muscle-invasive bladder cancer","volume":"157","author":"Herr","year":"2021","journal-title":"Urology"},{"key":"10.1016\/j.euf.2023.11.007_b0040","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3390\/pharmaceutics15030804","article-title":"Overview of side-effects of antibacterial fluoroquinolones: new drugs versus old drugs, a step forward in the safety profile?","volume":"15","author":"Rusu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.euf.2023.11.007_b0045","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ijantimicag.2018.04.014","article-title":"Adverse events of fluoroquinolones vs. other antimicrobials prescribed in primary care: a systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Tandan","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.euf.2023.11.007_b0050","first-page":"185","article-title":"Fluoroquinolones and the risk of aortopathy: a systematic review and meta-analysis","volume":"119","author":"Latif","year":"2020","journal-title":"WMJ"},{"key":"10.1016\/j.euf.2023.11.007_b0055","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/iju.14139","article-title":"Does asymptomatic bacteriuria affect the response to intravesical bacillus Calmette-Gu\u00e9rin?","volume":"27","author":"Herr","year":"2020","journal-title":"Int J Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456923002493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456923002493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T14:49:47Z","timestamp":1732632587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456923002493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2405456923002493"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2023.11.007","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quinolone Prophylaxis in Conjunction with Bacillus Calmette-Gu\u00e9rin Instillations for Bladder Cancer: Time To Reconsider the Evidence and Open the Quinolone Box?","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2023.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}